Business
Spectral Medical Provides Update on PMA Submission Timing for PMX-20R
TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the timing of its Premarket Approval (“PMA”) submission to the U.S. Food and Drug Administration (“FDA”) for its hemoadsorption device to treat endotoxic septic shock. Following recent interaction with the FDA, the Company now expects to submit its PMA around the end of Ap
About this update from Spectral Medical Inc
[{"type":"image","alt":"Spectral Medical Inc.","displaySize":"","headline":null,"caption":"Spectral Medical Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":216,"height":57,"url":"https://media.zenfs.com/en/globenewswire.com/c8dd3eb1a9d6f690331e05a27ac7bc09"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/P6nS4JHS3nYtocpBUIsxfw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c8dd3eb1a9d6f690331e05a27ac7bc09","width":216,"height":57}},"lazy":false},{"type":"text","content":"TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the timing of its Premarket Approval (“PMA”) submission to the U.S. Food and Drug Administration (“FDA”) for its hemoadsorption device to treat endotoxic septic shock.","length":394,"tagName":"p"},{"type":"text","content":"Following recent interaction with the FDA, the Company now expects to submit its PMA around the end of April to mid-May 2026, compared to its previously disclosed target of Q1 2026.","length":181,"tagName":"p"},{"type":"text","content":"The updated timing reflects ongoing FDA feedback to incorporate complete 12-month mortality data from the Tigris study into the PMA submission, as well as the completion of certain non-clinical module items, including human factors engineering testing, to support a complete and compliant submission.","length":300,"tagName":"p"},{"type":"text","content":"The Company believes the inclusion of complete 12-month mortality outcomes will further inform the FDA’s review and contribute to the totality of clinical evidence supporting PMX for the treatment of endotoxic septic shock.","length":223,"tagName":"p"},{"type":"text","content":"Spectral currently anticipates being in a position to report topline 12-month mortality data in late May or early June 2026, subject to the completion of additional data analysis.","length":179,"tagName":"p"},{"type":"text","content":"“We continue to work constructively with the FDA to ensure a high-quality PMA submission,” said Chris Seto, Chief Executive Officer of Spectral Medical. “The inclusion of longer-term mortality data and completion of the remaining non-clinical components are intended to support a c...